



BIOTECH CONSORTIUM INDIA LIMITED

28th
ANNUAL REPORT
2017 - 2018

BOARD OF DIRECTORS

Dr. V. P. Kamboj (Chairman)

Former Director, Central Drug Research Institute (CDRI), Lucknow

Dr. Bindu Dey

Secretary, Technology Development Board, New Delhi, Department of Science & Technology (DST), Ministry of Science & Technology, Govt. of India (Nominee of DST)

Shri S G Nadkarni

Chief General Manager, IDBI Bank Limited, New Delhi (Nominee of IDBI Bank Limited)

Dr. A.K. Rawat

Director, Department of Biotechnology (DBT), New Delhi, Ministry of Science & Technology, Govt. of India (Nominee of DBT)

Dr. (Mrs.) Manju Sharma

Former Secretary, Department of Biotechnology (DBT), New Delhi, Ministry of Science & Technology, Govt. of India

Dr. N. K. Singh

Project Director, National Research Center on Plant Biotechnology, IARI, New Delhi (Nominee of Indian Council of Agricultural Research (ICAR))

Shri P. R. Suresh

Ex-Executive Director of Specified Undertaking of Unit Trust of India (SUUTI), New Delhi (Nominee of SUUTI)

Dr. Ram A. Vishwakarma

Director, CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu (Nominee of Council of Scientific and Industrial Research (CSIR))

Dr. Purnima Sharma

Managing Director, Biotech Consortium India Limited

OTHER KEY DETAILS

CHIEF GENERAL MANAGER

Dr. Vibha Ahuja

DEPUTY GENERAL MANAGER

Dr. Shiv Kant Shukla

AGM (FINANCE) & COMPANY SECRETARY

Shri Mukesh Gupta

ASSISTANT GENERAL MANAGER(S)

Dr. Sanchita Chaudhary

Dr. Suchita Markan

MANAGER (S)

Smt. Anita Sharma

Shri Manoj Gupta

Shri Manish Sharma

Shri Vinod Kumar

DEPUTY MANAGERS

Shri Vineet Chhabra

Smt. Sherly Charles

Shri Krishan Singh Rawat

Smt. Shreya Sanghvi Malik

Dr. Yogmaya Verma

STATUTORY AUDITORS

M/s Surendra Subhash & Co.

BANKERS

Canara Bank

HDFC Bank Limited

IDBI Bank Limited

REGISTERED OFFICE

5th Floor, Anuvrat Bhawan,
210, Deen Dayal Upadhyaya Marg,
New Delhi – 110 002

NOTICE

Notice is hereby given that the Twenty Eight Annual General Meeting of the Members of Biotech Consortium India Ltd. will be held on Tuesday, 14th day of August 2018 at 10.30 am at the Registered Office of the company at 5th Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi-110002 to transact the following businesses:

ORDINARY BUSINESSSES

1. Adoption of Financial Statements

To receive, consider and adopt the audited Financial Statements of the company for the financial year ended March 31, 2018, together with the reports of the Board of Directors and the Auditors thereon.

2. Appointment of Director

To appoint a Director in place of Dr. V P Kamboj (DIN-00186440) who retires by rotation and being eligible, offers himself for reappointment.

3. Appointment of Director

To appoint a Director in place of Dr. Manju Sharma (DIN-01265049), who retires by rotation and being eligible, offers herself for reappointment.

4. Ratification of appointment of Auditors

To ratify appointment of Auditors of the company to hold office from the conclusion of this Annual General Meeting until the conclusion of next Annual General Meeting to be held after this meeting and to fix their remuneration and to pass with or without modification (s), the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Section 139 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditor) Rules, 2014, as amended from time to time, appointment of M/s Surendra Subhash & Co., Chartered Accountants (Firm Registration Number-003173N), as Auditors

of the company, be and are hereby ratified to hold office from the conclusion of this Annual General Meeting (AGM) till the conclusion of 29th Annual General Meeting to be held in the year 2019 to examine and audit the accounts of the company and that the Board of Directors be and are hereby authorized to fix such remuneration as may be mutually agreed upon between the Board of Directors and the Auditors”. (Refer Note 3).

SPECIAL BUSINESSSES

5. Appointment of Shri S G Nadkarni (DIN-03401830) as Director of the company

To consider and if thought fit, to pass with or without modification (s), the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** Shri S G Nadkarni (DIN-03401830), who was appointed as a Nominee Director of the IDBI Bank Limited in the 114th Board Meeting held on September 15, 2017 be and is hereby appointed as a Director of the company”.

6. Reappointment of Dr. Purnima Sharma as Managing Director of the company and approve her remuneration as per Section II of Part II of the Schedule V of the Companies Act, 2013

To consider and if thought fit, to pass with or without modification the following resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Sections 117, 152, 161, 170 196 and other applicable provisions, if any, read with Schedule V of the Companies Act, 2013 and any amendments thereof and as approved by the Board of Directors in their meeting held on June 04, 2018, the Members of the company hereby approves the reappointment of Dr. Purnima Sharma as Managing Director of the company with effect from May 23, 2018 for a period of five years on the following terms and conditions:

Basic Pay and Pay Scale:

A starting basic pay of Rs. 220300 in the pay scale 135700-4700-182700-4700-253200.

Dearness Allowance:

Linked to the all India Consumer Price Index and as followed by the all India financial institutions.

House Rent Allowance:

As per rules of the company. HRA will be payable at the rate of 30% of the basic pay. Alternately, leased accommodation may be provided by the company, the rent of which shall not exceed 50% of the basic pay.

Perquisites:**a. Ordinary Leave:**

As per rules of the company

b. Other Leave:

As per rules of the company

c. Leave Encashment:

As per rules of the company

d. Contributory Provident Fund:

As per rules of the company

e. Travelling Allowance:

As applicable to Directors of the company

f. Gratuity:

As per rules of the company

g. Medical Reimbursement and Medical Allowance:

For self and family, subject to a ceiling of half month's basic pay in a year as per rules of the company.

h. Medical Insurance:

As per rules of the company

i. Personal Accident Insurance:

Premium not exceeding Rs.1,500 per annum

j. Telephone and Internet:

Free telephone and Internet at residence at the expense of the company.

k. Car:

Free use of company's car for official purposes. Use of car for private purposes will be permitted on payment as per rules applicable to Chief Executive of the Company and as decided by the Board from time to time i.e presently Rs. 250 per 500 km and proportionately thereafter.

l. Club Membership:

Membership fee of one club.

m. Leave Fare Concession:

To and fro air fare for self and family to hometown/ any place once in a year. For traveling outside India, reimbursement will be restricted upto regular fare of a distance of 2100 km from Delhi (in India) of Air India or actual expenses incurred, whichever is lower.

n. Entertainment Allowance:

Not exceeding one month's pay plus DA in a year for official entertainment.

o. Termination of service:

On three months' notice from either side

With regard to all matters not specifically mentioned above, the terms and conditions of service shall be the same as those applicable to senior executives of the company from time to time. The terms and conditions may be altered as and when deemed necessary".

"RESOLVED FURTHER THAT pursuant to the provisions of section 197 read with schedule V of the Companies Act, 2013 and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification or re-enactment thereof for the time being in force) and pursuant to Articles of Association of the company, the Members of the company hereby approves that the remuneration approved by the Board be paid as minimum remuneration to Dr. Purnima Sharma irrespective of the fact whether company profits are inadequate in any financial years between April 01, 2018 to March 31, 2021.

NOTES:

1. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 relating to the Special Businesses to be transacted at the Annual General Meeting (AGM) is annexed hereto and forms part of this notice.
2. A Member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote on poll instead of himself/herself and such a proxy

need not be a Member of the company. Pursuant to the provisions of Section 105 of the Companies Act, 2013, a person can act as a proxy on behalf of not more than fifty Members and holding in aggregate not more than ten percent of the total share capital of the company. Members holding more than ten percent of the total share capital of the company may appoint a single person as proxy, who shall not act as a proxy for any other Member. The instrument of proxy, in order to be effective, should be deposited at the Registered Office of the company, duly completed and signed, not later than 48 hours before the commencement of the meeting. A Proxy Form is annexed to this Report. Proxies submitted on behalf of limited companies must be supported by an appropriate resolution / authority, as applicable.

3. A certificate from the Auditors have been received mentioning that they are eligible for the appointment and are not disqualified for the appointment under the Companies Act, 2013, the Chartered Accountant Act, 1949 and the Rules and Regulations made thereunder. Their appointment is as per the term provided under the Act and is within the limits laid down by or under the authority of the Act.
4. Pursuant to Section 101 and Section 136 of the Companies Act, 2013 read with relevant Rules made thereunder, companies can serve Annual Reports and other communications through electronic mode to those Members who have registered their e-mail address either with the company or with the Depository. Members who have not registered their e-mail address with the company can now

register the same by submitting a request to the company. Members holding shares in demat form are requested to register their e-mail address with their Depository Participant(s) only. Members of the company, who have registered their e-mail address, are entitled to receive such communication in physical form upon request.

5. Members may note that this Notice and the Annual Report for the year 2017-18 will also be available on the company website viz www.bcil.nic.in.
6. The route map showing directions to reach the venue of the twenty eight AGM is annexed.
7. The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013 will be available for inspection at the AGM.

By Order of the Board of Directors

(Mukesh Gupta)
AGM (Finance) & Company Secretary

Date : 13.07.2018

Place : New Delhi

Registered Office:

5th Floor, Anuvrat Bhawan,
210, Deendayal Upadhyaya Marg,
New Delhi – 110 002
CIN: U73100DL1990PLC041486

Annexure to Notice**EXPLANATORY STATEMENT SETTING OUT MATERIAL FACTS AS REQUIRED UNDER SECTION 102 OF THE COMPANIES ACT, 2013 IN RESPECT OF ITEMS OF SPECIAL BUSINESS AS PER THE NOTICE**

ITEM No. 5

Shri S G Nadkarni (DIN-03401830), CGM, IDBI Bank Limited was appointed as Nominee Director of the IDBI Bank Limited with effect from September 15, 2017 on the Board of the company in accordance with the Articles of Association of the company. It is proposed to regularize the appointment of Shri S G Nadkarni in the ensuing Annual General Meeting.

Your Directors recommend the resolution for approval of the Members.

None of the Directors or Key Managerial Personnel of the company and their relatives, other than Shri S G Nadkarni for his respective appointment, is concerned or interested, financially or otherwise, in the Resolution. The Board recommends the Ordinary Resolution as set out at item no. 5 for approval of the Members.

ITEM No. 6

Dr. Purnima Sharma was appointed as Managing Director by the Board in its 76th meeting held on May 23, 2008 for a period of five years and the appointment was approved by the Members of the company in the Eighteen Annual General Meeting held on July 16, 2008. The Board of Directors in its 95th meeting held on November 19, 2012 had renewed appointment Dr. Purnima Sharma as Managing Director of the company for another period of five years with effect from May 23, 2013 considering the excellent performance of the company during the last five years. The same was approved by the Members of the company in the Twenty Third Annual General Meeting held on September 05, 2013.

The Board of Directors in its 116th meeting held on March 26, 2018 had renewed appointment Dr. Purnima Sharma as Managing Director of the company for another period of five years with effect from May 23, 2018 considering that Dr. Purnima Sharma has diversified the activities of BCIL into different areas including international projects.

The Board in their 117th meeting held on June 04, 2018 had approved terms and conditions of reappointment of Dr. Purnima Sharma as Managing Director of the company. The Board considered that remuneration of Dr. Purnima Sharma, Managing Director of the company may exceed 5% of the net profits of the company during her tenure as Managing Director of the company. However, it will be well within limit of Rs. 84.00 lakhs as specified in Section II of Part II of the Schedule V of the Act. It is proposed that the remuneration approved by the Board be paid as minimum remuneration to Dr. Purnima Sharma irrespective of the fact whether company profits are inadequate in any financial years between April 01, 2018 to March 31, 2021.

As per the provisions of Sections 196 and 197 read with Schedule V of the Companies Act, 2013, the appointment and remuneration of the Managing Director should be approved by Board of Directors and Members of the company. The Board of Directors has approved and recommended the appointment of Dr. Purnima Sharma as Managing Director for a period of five years with effect from May 23, 2018 and remuneration package as per Section II of Part II of the Schedule V of the Companies Act, 2013 for the period 01/04/2018 to 31/03/2021 to the Members for approval.

Your Directors recommend the resolution for approval of the Members including the terms and conditions as set out in the resolution.

None of the Directors or Key Managerial Personnel of the company and their relatives, other than Dr. Purnima Sharma is concerned or interested, financially or otherwise, in the Resolution. The Board recommend the Special Resolution as set out at item no. 6 for approval of the Members.

The requisite information specified in Section II of Part II of the Schedule V is given below for kind perusal of the Members:

I. GENERAL INFORMATION

1. Nature of Industry

Consultancy in biotechnology

2. Date or expected date of commencement of commercial production

Existing company in operation since 1991

3. In case of new companies, expected date of commencement of activities as per project approved by the financial institute appearing in the prospectus

Not Applicable

4. Financial performance based on given indicators

Rs. in lakhs

Sl. No.	Particulars	2017-18	2016-17	2015-16
1.	Turnover	1005.52	916.24	803.80
2.	Net Profit/(Loss)	125.98*	168.49	137.04
3.	Paid-up share capital	537.00	537.00	537.00
4.	Reserves & Surplus	2091.86	1966.35	1796.25

* After absorbing unexpected provision of Rs. 55.45 lakhs towards gratuity liability made pursuant to amendment in the Payment of Gratuity Act, 1972.

5. Foreign investments or collaborators, if any

Nil

II. INFORMATION ABOUT THE APPOINTEE

1. Background details including recognition or awards

Dr. Purnima Sharma is a doctorate in Microbiology from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, the prestigious autonomous institution and deemed Medical University of national importance under the Ministry of Health, Government of India with Post Doctoral experience from IIT, Mumbai, and has to her credit many awards for excellence in academics.

She has vast experience in the area of IP management, technology transfer, project management and in coordinating diverse range of biotech projects of national and international relevance such as status studies, market analysis reports, feasibility studies etc. She has also coordinated the preparation of business plans for setting up biotechnology incubators and parks in different States. She is also a member of the National Academy of Sciences, the oldest academy of sciences in India. She is also a member of national and state level committees responsible for biotech development and commercialization including:

- Expert Committee on biotech parks of the Department of Biotechnology, Ministry of Science & Technology, Government of India, New Delhi;
- The Governing Council of the Chattisgarh Infotech & Biotech Promotion Society constituted under the Chairmanship of the Hon'ble Chief Minister of Chhattisgarh;

- The Review Committee of Foundation for Innovation and Technology Transfer (FITT), New Delhi;
- Society of Punjab Biotechnology Incubator, Mohali;
- Biotechnology Advisory Committee for establishment and promotion of Biotechnology Park in the state of Chhattisgarh of Chattisgarh Infotech & Biotech Promotion Society;
- Research Advisory Committee for Biotechnology and Life sciences of Shriram institute of Industrial Research, Delhi;
- Techno Assessment Committee of Agrinnovate India Ltd., New Delhi to facilitate in commercialization of technologies;
- Policy Advisory Vision Group on Biotechnology of Science & Technology Department, Government of Odisha;
- Board of Governors of IIIM – Technology Business Incubator, Jammu;
- Expert Committee Group of Department of Biotechnology, Government of India for considering the establishment of Atal Incubation Centre in NER under the Atal Innovation Mission etc.;
- Member of CII National Committee on Biotechnology (2018-19).

2. Past remuneration

Financial Years	Remuneration (Rs. in lakhs) *
2017-18	37.31
2016-17	33.94
2015-16	29.40

* Excluding retiral benefits.

3. Job profile and her suitability

Dr. Purnima Sharma serves as Managing Director of the company. She is in the overall control and management of the company. She is also the mentor behind all the policies of the company. She takes decisions in all strategic matters under supervision and guidance of the Board. To sustain the growth path, it is essential for the company to adequately remunerate her as per market norms. Accordingly, it is proposed to approve the existing remuneration package of Dr. Purnima Sharma.

4. Remuneration proposed

The detailed remuneration has been explained hereinabove in the resolution of the notice calling the Annual General Meeting of the company.

5. Comparative remuneration profile with respect to industry, size of the company, profile of the position and person

The remuneration package of Dr. Purnima Sharma is far below that drawn by the peers in the similar capacity in established companies engaged in consultancy e.g. Ernst & Young, McKinsey & Company, PWC etc.

6. Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel, if any

Apart from having the transactions as disclosed in Annual Report for the financial year ended March 31, 2018 pursuant to the provision of “Accounting Standard 18 (AS 18) and holding 10 equity shares of the company, there was no other pecuniary relationship directly or indirectly with the company or relationship with managerial personnel.

III. OTHER INFORMATION**1. Reason of loss or inadequate profits**

Since the appointment of Dr. Purnima Sharma on the Board, financial performance and visibility of the company has increased significantly which is evident from the following table:

Rs. in lakhs

Particulars	2005-06	2017-18	Growth (%)
Turnover	322.77	1005.52	211.52
Net Profit	73.53	125.98	71.33
Reserves & Surplus	211.19	2091.86	890.51

The remuneration is exceeding 5% of net profits of the company because the company is engaged in providing consultancy services in a specialized area of biotechnology and therefore, income and profitability are low and not expected to match with those observed in case of manufacturing companies.

2. Steps taken or proposed to be taken for improvement

The company is consistently expanding the scope of existing activities and is also proactively diversifying into new activities for which the skills and knowledge base is being strengthened.

3. Expected increase in productivity and profits in measurable terms

The above measures are expected to enhance the visibility of the company as a specialized consultancy agency in the area of biotechnology and also increase the profitability over the years at least by 3-7%.

IV. DISCLOSURES**1. Remuneration package of the managerial person**

Fully described in the item no. 6 & respective explanatory statement as stated above.

By Order of the Board of Directors

(Mukesh Gupta)
AGM (Finance) & Company Secretary

Date : 13.07.2018

Place : New Delhi

Registered Office:

5th Floor, Anuvrat Bhawan,
210, Deendayal Upadhyaya Marg,
New Delhi – 110 002
CIN: U73100DL1990PLC041486

DIRECTOR'S REPORT

To the Members,

Your Directors have pleasure in presenting the Twenty Eight Annual Report of the company along with the audited statement of accounts for the year ended 31st March 2018.

FINANCIAL RESULTS

(Rs. in lakhs)

Particulars	2017-2018	2016-2017
Income from Operating Activities	808.40	734.48
Income from Non Operating Activities	163.78	181.76
Exceptional and Extraordinary Items	33.34	0.00
GROSS INCOME	1005.52	916.24
Administrative & Other Expenses	832.69	659.31
Profit before Depreciation & Taxes	172.83	256.93
Add/(Less)		
Depreciation	(02.73)	(03.91)
Taxes	(44.12)	(84.53)
Net Profit/ (Loss)	125.98	168.49
Surplus brought forward from previous year	1952.01	1783.52
Surplus carried to Balance Sheet	2077.99	1952.01

During the year under review, income of your company increased to Rs. 1005.52 lakhs from Rs. 916.24 lakhs recorded during the previous year, registering a growth of 10.00% over the previous year. Your company achieved a profit of Rs. 125.98 lakhs during the year. The above said profit of Rs. 125.98 is after making a significant provision of Rs. 55.45 lakhs towards gratuity liability consequent upon amendment in the Payment of Gratuity Act, 1972.

OPERATIONS

Your company facilitated commercialization of biotech products and process by extending a range of business support services such as Intellectual Property Management and Technology Transfer, Consultancy, Biosafety Support, Project Management, Human Resource Development and Information Dissemination.

PROJECT MANAGEMENT

Your company continued the management of three prestigious long term programmes of Department of Biotechnology, Govt. of India (DBT) of immense national and international relevance namely National Certification System for Tissue Culture Raised Plants (NCS-TCP), North Eastern Region-Biotechnology Programme Management Cell (NER-BPMC) and School of International Biodesign (SIB).

During the year, your company successfully managed various activities of National Certification System for Tissue Culture Raised Plants (NCS-TCP). NCS-TCP is a quality management system for Indian plant tissue culture sector industry established under the Seeds Act 1966 and is first of its kind in the world. Your company has been managing NCS-TCP since its inception in 2006 and has played a key role in assisting DBT in its establishment and operationalization for production and distribution of quality tissue culture planting material. Concerted efforts made by your company has resulted in recognition of a significant number of companies, development of standard operating process, guidelines, tissue culture standards, certification labels, streamlining of testing and certification process etc. During the year, the main focus of NCS-TCP was towards the certification of tissue culture plants produced by the recognized companies. Towards this, stakeholders' meet was also organized to create wide-spread awareness about the importance of certification of tissue culture plants. So far more than 270 million tissue culture plants have been certified under NCS-TCP. This gross certified volume covers approximate 62000 hectare area. It is also significant to note that no major virus outbreak has been reported in tissue culture

plantations since the launch of NCS-TCP. Due to efforts made by your company in efficiently managing this programme, DBT has extended the tenure of NCS-TCP Management Cell at BCIL till March 31, 2020. It is also noteworthy that during the year, your company got a dynamic NCS-TCP web-portal developed which will strengthen the management of this programme by making it more robust and transparent.

The other major project of DBT managed by your company during the year is “North Eastern Region Biotechnology Programme Management Cell (NER-BPMC)” which is aimed at holistic biotech based development of the North Eastern Region (NER) of India and is being managed by your company since its inception in 2008. The NER-BPMC has proactively launched several region specific programmes in NER towards skilling of human resources, research infrastructure creation, introducing flagship R&D programmes and specific network programmes targeting local issues and development of entrepreneurship.

R&D initiatives taken include supporting 150 new projects under Twinning Programme to NER institutions in collaboration with leading national laboratories/universities; implementation of a special network programme on MDR-TB, scented rice of NER; propagation of disease free local Banana varieties and continuation of a unique programme on Chemical Ecology of NER in collaboration with leading institutions in Bangalore namely NCBS, IISc and UAS. A BSL-III laboratory is also being established at Guwahati. During the year, under the Overseas Associateship scheme, 43 (forty three) scientists have been selected to be trained in state-of-the-art subjects in reputed international institutes/universities. NER-BPMC also selected 110 new senior secondary schools under BLiSS programme besides successfully managing existing 88 schools in NER under BLiSS Programme.

Through these efforts, researchers from NER were able to publish more than 100 research papers in peer reviewed journals during the year, besides presentation of papers at national as well as international conferences. Researchers have also started filing patent applications. These initiatives have created an environment conducive for proactively carrying out R&D activities.

Your company continued to provide techno-legal services for management of DBT supported School of International Biodesign Programme (SIB) which is flagship programme of DBT implemented at AIIMS and IIT Delhi in collaboration with international partners aimed at development of innovative and affordable medical devices. Your company has been managing this programme since 2008. A new start-up company was established during the year named M/s Inochi Care Private Limited, Assam for further development and commercialisation of ‘Dual Therapy Dressing’ technology thereby increasing the total number of start-up companies established under SIB to 9.

Your company licensed the following two technologies during the year thereby increasing the number of technologies transferred under SIB to 18.

1. ‘Dual Therapy Dressing’ licensed to M/s. Inochi Care Private Limited, Assam on August 10th, 2017.
2. ‘Switchable Doppler Stethoscope’ licensed to M/s. Brun Health Private Limited, Telangana on August 10th, 2017.

Your company continued to provide diligent post-transfer monitoring and hand-holding support to the start-ups for facilitating expeditious commercial launch of their product.

The year 2017-18 witnessed the commercial launch of following two SIB products:

1. ‘A device and system for auditory impairment screening (Sohum)’ which was formally launched on July 17, 2017 in the gracious presence of Shri Y.S. Choudhary, the then Minister of State for Ministry of Science and Technology & Earth Sciences, Government of India.
2. ‘Removing foreign objects from a body cavity (Noxeno)’ formally launched on December 02, 2017 in the gracious presence of Dr. Harsh Vardhan, Hon’ble Minister of Science & Technology, Ministry of Environment, Forest and Climate Change and Ministry of Earth Sciences, Government of India.

Multiple Patent applications both Indian as well as International were filed during the year 2017-18 and

one European Patent Application, 6 Trademarks and 1 Industrial Design were granted.

Ms. Shivani Gupta, SIB, Fellow 2016 batch and one of the Directors of Start-up Company M/s. Inochi Care Private Limited, Assam was also awarded WInER Award for Women in Entrepreneurial Research (by TiE & BIRAC) on Women's Day by NASI.

PROJECT CONSULTANCY

Your company continued to extend services for facilitating setting up of biotech units. Your company prepared the feasibility report for setting up of production unit for cancer therapeutics at Special Economic Zone in Gurugram for a company. In addition your company assisted Government of West Bengal in preparation of DPRs for setting up of biotech park and biotech hubs in Kolkata, Kalimpong and Burdwan.

Your company also successfully completed a project on preparation of a strategy document for 'National Mission on Bioeconomy' sponsored by the Institute of Bioresources and Sustainable Development (IBSD), Imphal.

Your company was also commissioned for carrying out Impact Assessment Studies. During the year, under the ongoing project 'Online System for Student Feedback', your company successfully elicited feedback from post-graduate students of seventy DBT supported universities/institutes for assessing the quality of teaching to provide insights to DBT for strengthening teaching programme.

Your company also successfully carried out a study to assess the impact of two unique medical programmes of DBT being implemented in NER with the key objective of supporting development of medical infrastructure program and bringing together physicians & scientists to develop multidisciplinary research programs on diseases common to the region. For these DBT programmes namely 'Development/Upgrading Infrastructure in Medical Colleges in North Eastern States of India' and 'Research Grant to support MD/MS thesis in Medical Colleges in North Eastern States of India', your company examined and assessed the outcomes vis-à-vis stated objectives, identified gaps and made recommendations for strengthening and

improving the effectiveness of the programmes to create a greater impact in disease diagnosis and disease management and enable vibrant biomedical research environment in NER. The report has been accepted by DBT.

BIOSAFETY AND BIODIVERSITY SUPPORT SERVICES

Your company continued activities for providing support services in biosafety and biodiversity. Your company served as Project Coordination Unit for Phase II UNEP-GEF supported Capacity Building Project on Biosafety of Ministry of Environment, Forest and Climate Change (MoEF&CC) and Country Coordinator for "South Asia Biosafety Programme (SABP)" supported by USAID and implemented by ILSI Research Foundation, Washington, USA. Under the Phase-II Capacity Building Project, your company supported MoEF&CC in undertaking range of activities for stakeholders. Series of 15 workshops were organized for dissemination of knowledge products at state level in association with state agricultural universities. Resource documents in nine languages viz. English, Hindi, Bengali, Marathi, Telugu, Tamil, Kannada, Gujarati and Punjabi were provided to approximately 3000 participants that included scientists, researchers, students, agriculture department officials and progressive farmers. As part of SABP, your company organized the "5th Annual South Asia Biosafety Conference" in Bangalore, India from September 11-13, 2017, in association with ILSI Research Foundation, MoEF&CC, DBT, National Academies of Agriculture Sciences (NAAS) and Department of Environment, Govt. of Bangladesh. 185 participants from 10 countries attended the conference.

Training workshops were also organized for Institutional Biosafety Officers (IBOs) under the "ICAR Program on Biosafety Awareness and Compliance Readiness at a Pilot scale" for improving Institutional Capacity in Biosafety and Compliance Readiness in association with SABP.

Your company has also been associated with the Genetic Engineering Appraisal Committee (GEAC), MoEF&CC in launching e-Application system for ease of doing business on their new GEAC website i.e. <http://geacindia.gov.in>.

Your company continued to provide support services for the project “Centre for Biodiversity Policy and Law (CEBPOL)” for Norwegian Environment Agency and NBA. In addition, a study was initiated on assessing the disclosure of source of biological materials in Indian patents granted from 2013 to July, 2017 for NBA under CEBPOL.

Your company continued the preparation and circulation of newsletter in the area of biosafety and biodiversity including Biosafety Newsletter for MoEF&CC, SABP Newsletter for ILSI Research Foundation and Biodiversity Matters for NBA.

Considering the need of diversifying into new areas, your company submitted a proposal to United Nations Development Programme (UNDP) for organization of ‘Regional and National Consultations on Mainstreaming Biodiversity’ and was successful in receiving the sanction. The project is presently under implementation and five regional workshops have been organized during the year.

The workshops organized with the support from MoEF&CC, National Biodiversity Authority (NBA), UNDP and in association with the host State Biodiversity Boards aimed at sensitization of concerned stakeholders and creating awareness on National Biodiversity Action Plan (NBAP) and National Biodiversity Targets (NBTs), as well as for seeking inputs for preparation of India’s sixth National Report to the Convention on Biological Diversity (CBD).

INTELLECTUAL PROPERTY MANAGEMENT AND TECHNOLOGY TRANSFER SERVICES

During the year, your company continued to undertake IP assignments for Indian biotech industry, research institutes, universities and government agencies. These covered IP due diligence, freedom to operate searches, prior art searches, patent drafting and filing, trademark, design and copyright related advisory and filing.

Under the technology transfer initiatives, your company continued to provide technology transfer services including technology evaluation for commercial

feasibility to IIT Madras, IIT Kanpur, ICMR and RCB. Your company facilitated the licensing of technology entitled “A polyherbal formulation for Genital microbial pathogens” developed by M/s Talwar Research Foundation, New Delhi in June 2017 to M/s Bipla Drug Laboratories (Pvt.) Ltd, Kottayam. In 2017-18, your company was empanelled with BIRAC as Technology Transfer firm and MoUs with IIT Roorkee and BIRAC were executed for providing them Technology Transfer Services.

HUMAN RESOURCE DEVELOPMENT

Your company is pleased to inform that under the area of Human Resource Development, your company coordinated the prestigious “DBT-JRF” programme. This programme aims at providing fellowships to biotechnology students interested in pursuing research in institutes/universities across the country. The candidates were selected based on an online test “Biotechnology Eligibility Test (BET)”. Presently, more than 850 students are pursuing Ph.D. at 220 universities/institutes, under the programme.

This year, your company was also awarded the Bioinformatics National Certification (BINC) programme to identify and certify bioinformatics professionals to improve their employment opportunities. The successful post-graduate candidates are also eligible for availing Junior Research Fellowship (JRF) for pursuing research and/or Ph.D. in Indian Institutes/Universities. Your company carried out a three tier selection process for identifying successful candidates consisting of an online test with objective type multiple choice questions followed by a theory paper and practicals.

Your company continued to coordinate the “Biotech Industrial Training Programme (BITP)” which is aimed at providing practical industrial exposure for six months to biotechnology and bioinformatics students and in the process helping industry to identify prospective manpower. BITP also included a separate training programme for students of north eastern states. This year 854 trainees were placed in 171 biotech and

bioinformatics companies all over India. Your company has been able to elicit encouraging response from the stakeholders as evidenced from increasing participation from universities and companies particularly innovative start-ups and medium scale companies which has resulted in significant improvement in the quality of training imparted to the students. Your company arranged training in diverse areas such as clinical trials, contract manufacturing, management of Intellectual Property etc which offer good career opportunities. The programme is gaining popularity among biotech engineers as well. About 33% of trainees were able to find job placements following training under BITP.

Your company has been recently awarded the management of DBT- Conference, Travel, Exhibition, Popular Lecture (CTEP) programme. Under this programme, DBT provides financial assistance towards organizing Conference/ Seminar/ Symposium/ Workshop and Travel support to researchers for presenting their papers in international conferences, organising stalls in exhibitions, organising popular lectures etc. The programme is being implemented by your company through a dynamic online software programme which enables efficient management of various activities such as registration of applicants, verification of documents, scrutinizing of proposals, coordination of meetings, processing of applications etc.

During the year, your company successfully organized four training programmes under “Comprehensive Capacity Building Programme on Commercial Micro-propagation in Africa’ with financial support from the Ministry of External Affairs (MEA) under the third India Africa Forum Summit (IAFS-III). The programme witnessed training of 94 candidates from twenty African countries. The programme focused on providing hands-on training in commercial tissue culture, virus indexing and genetic fidelity testing of tissue culture plants. The training earned appreciation from candidates as well as from MEA. This project is expected to contribute significantly in strengthening the African plant tissue culture industry sector. During current financial year, your company plans to train another 100 African candidates in different categories such as scientists, laboratory staff, production manager, students and progressive growers.

ENTREPRENEURSHIP DEVELOPMENT

During the year, your company took a number of initiatives in the important area of entrepreneurship development. Your company assisted the Indian Institute of Technology, Kanpur for promotion of their Bio-incubator. Your company helped the Bio-incubator attract incubates for its facility by organizing bioentrepreneurship boot-camp and hackathon, organizing roadshows at other research institutions/universities and also provided advisory services for promoting the facility.

Your company was also engaged for the promotion of the Technology Business Incubator (TBI) of CSIR – Indian Institute of Integrative Medicine (IIIM), Jammu. Your company assisted IIIM-TBI in preparing a comprehensive strategy for promoting its facility, designed advertising material, created awareness through mailers, advertisements and social media, facilitated TBI’s participation in tradeshows and exhibitions and in organizing skill development programmes for optimal utilization of its facility.

Your company was commissioned by the National Academy of Sciences, India (NASI) to prepare a publication documenting, the success stories of young biotechnology entrepreneurs in the country. The publication – ‘Trailblazers – Mapping the Journey of Young Bioentrepreneurs’ was released by Shri C. Vidyasagar Rao, Governor of Maharashtra and other eminent dignitaries during 87th Annual Session of NASI and Symposium at University of Pune on 8th December, 2017. The book highlights the success stories of 65 entrepreneurs working on biotechnology innovations in areas such as therapeutics, biomedical devices, nutrition, tissue culture, biofertilizers, etc. and is an important resource document for inspiring prospective entrepreneurs and providing them valuable information for starting & building their own businesses in biotechnology.

Your company also organised a workshop on “Bioentrepreneurship Development” on February 27, 2018 at New Delhi. Shri Amitabh Kant, CEO, NITI Aayog delivered the special address on the potential of biotechnology and the role of bioentrepreneurs in realizing the huge unexploited potential. A resource

book on “Bioentrepreneurship Development” prepared by your company was also released by Shri Kant during the said workshop. The objective of the programme was to create awareness about the various aspects of entrepreneurship including identifying business opportunities, developing business plan, different models of commercialization, funding opportunities, brand building, intellectual property management, accessing markets, etc. The programme aimed to inspire the budding entrepreneurs by educating them about the pathway to set up their own enterprise as well as assist the existing entrepreneurs in taking forward their ventures. Success stories and case studies of successful bioentrepreneurs were also presented during the programme. More than 200 participants from Biotech Industry and Research Institutions participated in the event.

CLINICAL TRIAL MANAGEMENT SERVICES

During the year, your company introduced a new service towards Clinical Trial Management aimed at supporting research institutes, industry and universities engaged in drug development. Your company secured its very first project under this category of services involving “Management of Phase III clinical trial of three single dose treatment regimens of Fungisome for Visceral Leishmaniasis (VL) in India” from M/s Lifecare Innovations Pvt. Ltd. Gurugram. The study is being undertaken in a timeline based manner and the patient recruitment has already started in March 2018. Your company is actively exploring new project opportunities from research institutes engaged in drug discovery.

INFORMATION SERVICES

As a part of the Distributed Information Sub-Center (DISC) of DBT, your company provided value added information services to the stakeholders. The members of Biotechnology Club of your company consisting of industry, research institutions, universities and individuals were kept abreast with the latest developments in biotechnology through regular information updates and newsletters.

FUTURE STRATEGY

Your company will continue to expand the scope of services under its existing operational areas and would

explore business opportunities with other government departments and non-government organization. In addition, your company would proactively work towards diversifying into newer areas by establishing strategic linkages with organizations and experts offering complimentary expertise. Your company will continue to enhance the skill base of existing personnel and also engage suitable professionals in line with the company’s future strategy.

RESOURCES

Your company’s finances were based on income generated from its existing resources and operations. There was no increase in the share capital and no funds were borrowed during the year. As desired by the institutional shareholders, most of the shares have been dematerialized through M/s Sky Line Services Pvt. Ltd., New Delhi as registrars. The shares are held in electronic form with the National Securities Depository Limited (NSDL).

AUDITORS’ REPORT

Observations of the Auditors read together with relevant notes to accounts are self-explanatory and therefore no further clarification is required.

PERSONNEL

Employees were deputed for training programmes, seminars and workshops to enhance their exposure, expertise and participation skills. No employee received remuneration exceeding the limits prescribed under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION

Your company is a service organization and is not engaged in any direct manufacturing activity. Therefore, conservation of energy and technology absorption are not under the purview of its activities.

FOREIGN EXCHANGE EARNINGS AND OUTGO

Your company earned Rs. 75.37 lakhs in foreign currency towards consultancy fee and spent Rs. 1.70 lakhs in foreign currency.

AUDITORS

The appointment of M/s Surendra Subhash & Company, Chartered Accountants, New Delhi, is subject to ratification at the ensuing Annual General Meeting. They have furnished a certificate mentioning that they are eligible for the appointment and are not disqualified for the appointment under the Companies Act, 2013, the Chartered Accountant Act, 1949 and the rules and regulations made thereunder. Their appointment is as per the term provided under the Act and is within the limits laid down by or under the authority of the Act.

Your Directors recommend ratification of their appointment to hold office from the conclusion of this Annual General Meeting until the conclusion of next Annual General Meeting to be held after this meeting.

INTERNAL FINANCIAL CONTROLS

The company has in place well defined and adequate internal controls commensurate with the size of the company and the same were operating effectively throughout the year.

DIRECTORS

In accordance with the relevant provisions of the Articles of Association of the company and provisions of Companies Act, 2013, Dr. V P Kamboj (DIN-00186440) and Dr. Manju Sharma (DIN- 01265049), Directors retiring by rotation at the forthcoming Annual General Meeting and being eligible, offer themselves for reappointment.

Shri S G Nadkarni (DIN-03401830), Chief General Manager, IDBI Bank Limited and Nominee Director, IDBI Bank Limited was inducted as Director by the Board on September 15, 2017. A declaration has been received from Shri S G Nadkarni that he is not disqualified to become a Director under the Companies Act, 2013.

During the year, Shri Rajeev Kumar, CGM, IDBI Bank Limited and Nominee Director, IDBI Bank Limited ceased to be Director following nomination by IDBI Bank Limited of Shri S G Nadkarni. Shri Vijay Pal, General Manager, IFCI Limited and Nominee Director, IFCI Limited ceased to be Director with effect from

April 26, 2018 following withdrawal of nomination by IFCI Limited. The Board placed on record deep and sincere appreciation for the contributions made by Shri Rajeev Kumar and Shri Vijay Pal during their tenure as Directors of the company.

Considering that Dr. Purnima Sharma has diversified the activities of your company into different areas including international projects and outstanding performance of Dr. Purnima Sharma, the Board in its 116th meeting held on March 26, 2018 has approved reappointment of Dr. Purnima Sharma as Managing Director of the company with effect from May 23, 2018 for a period of five years with two advance increments. The Board in its meeting held on June 04, 2018 had approved the terms and conditions of reappointment of Dr. Purnima Sharma as Managing Director of the company with effect from May 23, 2018 for a period of five years. The Board also approved the payment of remuneration to the Managing Director as per Schedule V of the Act for the period April 01, 2018 to March 31, 2021. The resolutions for reappointment and remuneration of Dr. Purnima Sharma are placed in the agenda item for approval of the Members.

EXTRACT OF ANNUAL RETURN

An extract of Annual Return pursuant to Section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules 2014 is given at Annex 1 and forms part of Directors' Report.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

All contracts / arrangements / transactions entered by the company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. None of the transactions with any of related parties were in conflict with the company's interest.

The company's major related party transactions were with IDBI Bank Limited who has invested 27.93% in the capital of the company. The particulars of contracts

or arrangements with related parties referred to in sub-section (1) of section 188 in the Form AOC-2 is given at Annex 2 and forms part of Directors' Report.

Your Directors draw attention of the members to the Note 20.3b of the financial statement which sets out related party disclosures.

MEETINGS OF THE BOARD & ITS COMMITTEES

Four meetings of the Board were held during the year on June 28, 2017, September 15, 2017, December 22, 2017 and March 26, 2018. Attendances of the Directors during these meetings are given below:

Name of the Director	Board Meeting No. and Date				No. of Board meeting held during tenure	No. of Board meeting attended	Attendance (%)
	113 28-06-17	114 15-09-17	115 22-12-17	116 26-03-18			
Dr. V. P. Kamboj	Yes	Yes	Yes	Yes	4	4	100%
Dr. Bindu Dey	Yes	No	No	Yes	4	2	50%
Shri Rajeev Kumar *	No	NA	NA	NA	1	0	0%
Shri S G Nadkarni**	NA	Yes	No	Yes	3	2	67%
Shri Vijay Pal	Yes	No	Yes	No	4	2	50%
Dr. A K Rawat	No	Yes	Yes	Yes	4	3	75%
Dr. (Mrs.) Manju Sharma	Yes	Yes	Yes	Yes	4	4	100%
Dr. N K Singh	Yes	Yes	No	Yes	4	3	75%
Shri P. R. Suresh	Yes	Yes	Yes	No	4	3	75%
Dr. Ram A Vishwakarma	No	Yes	Yes	No	4	2	50%
Dr. Purnima Sharma	Yes	Yes	Yes	Yes	4	4	100%

* Ceased to be director wef 20-07-2017

** Joined the Board wef 15-09-2017

Two meetings of the Financial Advisory Committee of the Board were held during the year on June 27, 2017 and December 21, 2017. Attendances of the Directors during these meeting are given below:

Name of the Director	Meeting No. and Date	No. of meeting held during tenure	No. of meeting attended	Attendance (%)	
	7 27-06-17	8 21-12-17			
Shri P. R. Suresh	Yes	Yes	2	2	100%
Shri Rajeev Kumar *	No	NA	1	0	0%
Shri S G Nadkarni**	NA	No	1	0	0%
Shri Vijay Pal***	Yes	Yes	2	2	100%
Dr. Purnima Sharma	Yes	Yes	2	2	100%

* Ceased to be Member of the Committee of Board wef 20-07-2017

** Joined the Committee of Board wef 15-09-2017

*** Ceased to be Member of the Committee of the Board wef 26-03-2018

CORPORATE SOCIAL RESPONSIBILITY

The provisions of Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules 2014 were not applicable to the company.

SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

During the year under review, no companies had become or ceased to be company's subsidiaries, joint ventures or associate companies.

PARTICULARS OF LOANS GIVEN, INVESTMENTS MADE, GUARANTEES GIVEN AND SECURITIES PROVIDED

During the year under review, the above said clause was not applicable to the company.

GENERAL

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

1. Details relating to deposits covered under Chapter V of the Act.
2. Issue of equity shares with differential rights as to dividend, voting or otherwise.
3. Issue of shares (including sweat equity shares) to employees of the company under any scheme.
4. The Managing Director nor the Whole-time Directors of the company received any remuneration or commission from any of its subsidiaries.
5. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and company's operations in future.

Your Directors further state that during the year under review, no cases were filed under the "Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013".

DIRECTORS' RESPONSIBILITY STATEMENT

Your Directors confirm:

- 1) that in the preparation of annual accounts, the

applicable accounting standards had been followed along with proper explanation relating to material departures;

- 2) that the directors had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year 2017-2018 and of the profit and loss of the company for that period;
- 3) that the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- 4) that the directors prepared the annual accounts on a going concern basis;
- 5) that the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

ACKNOWLEDGEMENTS

Your Directors wish to express their gratitude to the DBT for technical and financial support extended to your company. They also wish to thank the laboratories who have been the sources of technologies, various other Central and State Government departments, agencies and international sponsors including MoEF&CC, MOA, MEA, MSME, BIRAC, UNDP, UNIDO, UNEP, ILSI Research Foundation, DST, DSIR, ICAR, ICMR, CSIR, TDB, the financial institutions including IDBI, IFCI, ICICI Bank, IFCIVCL and SUUTI for their continued support and guidance and all the company's clients for the opportunity to serve them. Your Directors also place on record their appreciation of the devoted services rendered by the employees of the company.

For and on behalf of the Board of Directors

Date: 04.06.2018
Place: New Delhi

(V.P. Kamboj)
Chairman

EXTRACT OF ANNUAL RETURN

as on the financial year ended on 31.3.2018

[Pursuant to Section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:

i)	CIN	U73100DL1990PLC041486
ii)	Registration Date	14/09/1990
iii)	Name of the Company	Biotech Consortium India Limited (BCIL)
iv)	Category / Sub-Category of the Company	Public Limited Company
v)	Address of the Registered office and contact details	5th Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi-110002, Tel: 91-11-23219064-67, Fax No. 91-11-23219063 Email: info.bcil@nic.in , Website: www.bcil.nic.in
vi)	Whether listed company	No
vii)	Name, Address and Contact details of Registrar and Transfer Agent	Skyline Financial Services Pvt. Ltd. D-153A, First Floor, Okhla Industrial Area, Phase-1, New Delhi-110020 Tel: 91-11-26812682-83

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
1.	Consultancy in biotechnology	NA	83%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES -

Sl. No	NAME AND ADDRESS OF THE COMPANY	CIN/GLN	HOLDING/ SUBSIDIARY/ ASSOCIATE	% of shares held	Applicable Section
1	IDBI Bank Limited, IDBI Tower, WTC Complex, Cuffe Parade, Colaba, Mumbai-400005	L65190MH2004GOI148838	Associate	27.93*	Section 2(6) of Companies Act, 2013

* Shares held by IDBI Bank Ltd. in BCIL

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
a) Individual/ HUF	---	---	---	---	---	---	---	---	---
b) Central Govt	---	---	---	---	---	---	---	---	---
c) State Govt (s)	---	---	---	---	---	---	---	---	---
d) Bodies Corp.	---	---	---	---	---	---	---	---	---
e) Banks / FI	30,00,005	10,00,002	40,00,007	74.48	30,00,005	10,00,002	40,00,007	74.48	---
f) Any Other....	---	---	---	---	---	---	---	---	---
Sub-total (A) (1)	30,00,005	10,00,002	40,00,007	74.48	30,00,005	10,00,002	40,00,007	74.48	---
(2) Foreign									
a) NRIs - Individuals	---	---	---	---	---	---	---	---	---
b) Other – Individuals	---	---	---	---	---	---	---	---	---
c) Bodies Corp.	---	---	---	---	---	---	---	---	---
d) Banks / FI	---	---	---	---	---	---	---	---	---
e) Any Other....	---	---	---	---	---	---	---	---	---
Sub-total (A) (2)	---	---	---	---	---	---	---	---	---
Total shareholding of promoters (A)= (A) (1) + (A) (2)	30,00,005	10,00,002	40,00,007	74.48	30,00,005	10,00,002	40,00,007	74.48	---
B Public shareholding									
1. Institutions									
a) Mutual Funds	---	---	---	---	---	---	---	---	---
b) Banks / FI	---	---	---	---	---	---	---	---	---
c) Central Govt	---	---	---	---	---	---	---	---	---
d) State Govt (s)	---	---	---	---	---	---	---	---	---
e) Venture Capital Funds	---	---	---	---	---	---	---	---	---
f) Insurance Companies	---	---	---	---	---	---	---	---	---
g) FIIs	---	---	---	---	---	---	---	---	---
h) Foreign Venture Capital Funds	---	---	---	---	---	---	---	---	---
i) Others (specify)	---	---	---	---	---	---	---	---	---
Sub-total (B) (1)	---	---	---	---	---	---	---	---	---
2. Non- Institutions									
a) Bodies Corp.									
i) Indian	3,00,000	10,60,000	13,60,000	25.33	3,00,000	10,60,000	13,60,000	25.33	---
ii) Overseas	---	---	---	---	---	---	---	---	---
b) Individuals	---	---	---	---	---	---	---	---	---

Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh	---	20	20	---	---	20	20	---	---
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh	---	---	---	---	---	---	---	---	---
c) Others	---	10,000	10,000	0.19	---	10,000	10,000	0.19	---
Sub-total (B) (2)	3,00,000	10,70,020	13,70,020	25.52	3,00,000	10,70,020	13,70,020	25.52	---
Total Public Shareholding (B)=(B) (1)+(B)(2)	3,00,000	10,70,020	13,70,020	25.52	3,00,000	10,70,020	13,70,020	25.52	---
C. Shares held by Custodian for GDRs & ADRs	---	---	---	---	---	---	---	---	---
Grand Total (A+B+C)	33,00,005	20,70,022	53,70,027	100	33,00,005	20,70,022	53,70,027	100	---

(ii) Shareholding of Promoters

Sl. No.	Shareholder's Name	Share holding at the beginning of the year			Share holding at the end of the year			
		No. of Shares	%of total Shares of the company	%of Shares Pledged/ encumbered to total shares	No. of Shares	%of total Shares of the company	%of Shares Pledged/ encumbered to total shares	% change in share holding during the year
1.	IDBI Bank Limited	15,00,004	27.93	NA	15,00,004	27.93	NA	---
2.	IFCI Limited	10,00,001	18.62	NA	10,00,001	18.62	NA	---
3.	ICICI Bank Ltd.	1	--	NA	1	--	NA	---
4.	IDBI Trusteeship Services Limited (ICICI Strategic Investments Fund)	10,00,000	18.62	NA	10,00,000	18.62	NA	---
5.	IFCI Venture Capital Funds Ltd.	2,00,001	3.72	NA	2,00,001	3.72	NA	---
6.	Administrator of the Specified Undertaking of the Unit Trust of India	3,00,000	5.59	NA	3,00,000	5.59	NA	---
	Total	40,00,007	74.48		40,00,007	74.48		

(iii) Change in Promoters' Shareholding (please specify, if there is no change)

Sl. No.	Particulars	Shareholding at the beginning of the year		Cumulative Share holding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	At the beginning of the year	40,00,007	74.48	40,00,007	74.48
2.	Date wise Increase / Decrease in Promoters Share holding during the year	---	---	---	---
3	At the end of the year	40,00,007	74.48	40,00,007	74.48

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Top 10 Shareholders				
1	At the beginning of the year	6,50,000	12.09	6,50,000	12.09
2.	Date wise Increase / Decrease in Share holding during the year	---	---	---	---
3.	At the End of the year (or on the date of separation, if separated during the year)	6,50,000	12.09	6,50,000	12.09

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.	Particulars	Share holding at the beginning of the year		Cumulative Share holding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
	For Each of the Directors and KMP				
1.	At the beginning of the year	10	---	10	---
2.	Date wise Increase / Decrease in Share holding during the year	---	---	---	---
3.	At the End of the year	10	---	10	---

V. INDEBTEDNESS**Indebtedness of the Company including interest outstanding/accrued but not due for payment**

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	---	---	---	---
ii) Interest due but not paid	---	---	---	---
iii) Interest accrued but not due	---	---	---	---
Total (i+ii+iii)	---	---	---	---
Change in Indebtedness during the financial year				
• Addition	---	---	---	---
• Reduction	---	---	---	---
Net Change	---	---	---	---
Indebtedness at the end of the financial year				
i) Principal Amount	---	---	---	---
ii) Interest due but not paid	---	---	---	---
iii) Interest accrued but not due	---	---	---	---
Total (i+ii+iii)	---	---	---	---

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL**A. Remuneration to Managing Director, Whole-time Directors and/or Manager:**

Sl. No.	Particulars of Remuneration	Name of MD/WTD/Manager	Total Amount
		Dr. Purnima Sharma	
1.	Gross salary	Rs. in lacs	Rs. in lacs
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	36.85	36.85
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	0.46	0.46
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	---	---
2.	Stock Option	---	---
3.	Sweat Equity	---	---
4.	Commission - as % of profit - others, specify...	---	---
5.	Others, please specify	---	---
	Total (A)	37.31	37.31
	Ceiling as per the Act	84.00	84.00

B. Remuneration to other directors:

Rs. in Lacs

Sl. No.	Particulars of Remuneration	Name of Directors				Total Amount
1.	Independent Directors					
	• Fee for attending board committee meetings	----	----	----	----	----
	• Commission	----	----	----	----	----
	• Others, please specify	----	----	----	----	----
	Total(1)	----	----	----	----	----
2.	Other Non - Executive Directors					
	• Fee for attending board committee meetings			1.37		
	• Commission			--		
	• Others, please specify			--		
	Total (2)			1.37		
	Total (B) = (1+2)			1.37		
	Total Managerial Remuneration			Rs. 38.68		
	Overall Ceiling as per the Act			Rs. 84.00 lacs for Managing Director and Rs. 1.00 lacs per meeting for non executive director.		

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

Rs. in Lacs

Sl. no.	Particulars of Remuneration	Key Managerial Personnel			
		CEO	Company Secretary	CFO	Total
1.	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	----	18.94	----	18.94
	(b) Value of perquisites u/s 17(2) of Income-tax Act,1961	----	0.15	----	0.15
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	----	----	----	----
2.	Stock Option	----	----	----	----
3.	Sweat Equity	----	----	----	----
4.	Commission - as % of profit -others, specify...	----	----	----	----
5.	Others, please specify	----	----	----	----
	Total	----	19.09	----	19.09

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty/ Punishment/ Compounding fees imposed	Authority [RD/NCLT/ COURT]	Appeal made, if any (give details)
A. COMPANY					
Penalty	-----	----	----	---	-----
Punishment	-----	----	----	---	-----
Compounding	-----	----	----	---	-----
B. DIRECTORS					
Penalty	-----	----	----	---	-----
Punishment	-----	----	----	---	-----
Compounding	-----	----	----	---	-----
C. OTHER OFFICERS IN DEFAULT					
Penalty	-----	----	----	---	-----
Punishment	-----	----	----	---	-----
Compounding	-----	----	----	---	-----

Annex. 2

AOC-2

(Pursuant to Clause (h) of Sub-Section (3) of Section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)
Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in Sub-Section (1) of Section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso there to

i. Details of contracts or arrangements or transactions not at arm's length basis

S. N.	Name of the related party and nature of relationship	Nature of contracts/ arrangements /transactions	Duration of the contracts / arrangements /transactions	Salient terms of the contracts or arrangements or transactions including the value, if any	Justification for entering into such contracts or arrangements or transactions	Date of approval by the Board	Amount paid as advances, if any:	Date on which the special resolution was passed in general meeting as required under first proviso to Section 188
NIL								

ii. Details of material contracts or arrangement or transactions at arm's length basis

S.N.	Name of the related party and nature of relationship	Nature of contracts/ arrangements/ transactions	Duration of the contracts / arrangements/ transactions	Salient terms of the contracts or arrangements or transactions including the value, if any:	Date(s) of approval by the Board, if any:	Amount paid as advances, if any:
1.	Dr. Purnima Sharma Sh. Mukesh Gupta KMPs	Payment of salaries	N.A.	N.A.	N.A.	N.A.
2.	IDBI Bank Limited Associate Company	Banking transactions: Three current accounts and term deposits	N.A.	N.A.	N.A.	N.A.

INDEPENDENT AUDITORS' REPORT

To the Members of

Biotech Consortium India Limited

Report on the Financial Statements

We have audited the accompanying financial statements of Biotech Consortium India Limited ("the company"), which comprise the Balance Sheet as at March 31, 2018, the Statement of Profit and Loss, the statement of change in equity, the Cash Flow Statement for the year then ended and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The company's management and Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the company in accordance with the accounting principles generally accepted in India including the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit.

In conducting our Audit we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder and the order issued under section 143(11) of the Act.

We have conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatements.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by Management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence, we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2018, and its profit, the changes in equity and its cash flows for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Ministry of Corporate Affairs in terms of sub-section (11) of Section 143 of the Act, we give in the **Annexure A** a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable to the company.
2. As required by Section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b) In our opinion, proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - c) The Balance Sheet and Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account;
 - d) In our opinion, the Balance Sheet, Statement of Profit and Loss and the Cash Flow Statement, comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014;
 - e) On the basis of written representations received from the directors as on March 31, 2018, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2018, from being appointed as a director in terms of Section 164(2) of the Act;
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
 - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - (i) The company has disclosed the impact of pending litigations on its financial position in its financial statements.
 - (ii) The company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, and as required on long-term contracts including derivative contracts
 - (iii) There is no amount required to be transferred to the Investor Education and Protection Fund during the year by the company.

For Surendra Subhash & Co.
Chartered Accountants
FRN: 03173N

S.C. Gupta
(Partner)

Place: New Delhi
Date: 04.06.2018

Membership No. : **83121**

The Annexure A referred to in paragraph 1 under the heading “Report on Other Legal and Regulatory Requirements” of our report of even date to the Members of Biotech Consortium India Limited on the Financial Statements of the company for the year ended 31st March, 2018

On the basis of such checks as we considered appropriate and according to the information and explanation given to us during the course of our audit, we report that:

1. Fixed Assets

- a. The company is maintaining proper records showing full particulars, including quantitative details and situation of fixed assets.
- b. As explained to us, these fixed assets have been physically verified by the management at reasonable intervals, which in our opinion is reasonable having regard to the size of the company and the nature of its assets. No material discrepancies between the book records and the physical assets have been noticed on such verification.
- c. The company does not own any immovable property.

2. Inventories

The Company is in the business of providing Consultancy services and does not have any physical inventories. Accordingly, reporting under clause 3 (ii) of the Order is not applicable to the Company.

3. Transactions with Parties covered under Section 189 of the Companies Act, 2013

According to the information and explanations given to us, the company has not granted any loans, secured or unsecured to companies, firm or other parties covered in the register maintained under section 189 of the Companies Act, 2013 .

In view of the above, para (a) & (b) of the Clause under reference are not applicable.

4. Loan, Advance, guarantees covered under section 185/186 of the Companies Act , 2013

The Company has not given any Loan, Advance, & Guarantees to the person covered under section 185 of the Companies Act, 2013.

5. Deposits

The Company has not accepted deposits during the year and does not have any unclaimed deposits as at March 31, 2018 and therefore, the provisions of the clause 3 (v) of the Order are not applicable to the Company.

6. Cost Records

The maintenance of cost records has not been specified by the Central Government under section 148(1) of the Companies Act, 2013 for the business activities carried out by the Company. Thus reporting under clause 3(vi) of the order is not applicable to the Company.

7. Statutory Dues & Requirements

- a. According to the information and explanation given to us and on the basis of our examination of the books of account, the company has generally been regular in depositing undisputed statutory dues including provident fund, employees’s state insurance, income tax, sales tax, goods and service tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues during the year with the appropriate authorities.

No amount payable in respect of the statutory dues as mentioned above were outstanding as at March 31, 2018 for a period of more than six months from the date they become payable.

- b. According to the information and explanation given to us, there are no amounts in respect of income tax/ sales tax/ wealth tax/service tax/duty of customs/ duty of excise,value added tax, GST that have not been deposited with the appropriate authorities on account of any dispute, except the following:

S. No.	Name of the statute	Nature of dues	Amount unpaid (Rs.)	Assessment year to which the amount relates	Forum where dispute is pending
1.	Income Tax Act, 1961	Demand raised u/s 115WE.	2,02,078/-*	2009-10	DCIT, Circle 5(1)
2.	Income Tax Act, 1961	TDS Demand	1,87,780/-*	2008-09 to 2018-19	DCIT, Circle 73(1)

* Application for rectification is yet to be disposed off by the Income Tax Department.

8. The company has not taken any loans from financial institutions or banks, government or have no dues to debenture holders, hence this clause is not applicable.
9. The company has not raised any initial public offer and also not taken any term loans during the year, hence the clause is not applicable.
10. Based upon the audit procedures performed and on the basis of information and explanation given to us by the management, we report that no fraud on or by the company has been noticed or reported during the year.
11. Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act
12. The company is not a Nidhi Company and therefore the provisions as applicable to a Nidhi Company are not applicable to the company.
13. All transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013
14. According to the records of the company, the company has not made any preferential allotment or private placement of shares fully or partly convertible debentures during they year under review and hence reporting under clause 3 (xiv) of the Order is not applicable to the Company.
15. During the year, the company has not entered into any non-cash transactions with directors or persons connected with them.
16. In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.

For Surendra Subhash & Co.
Chartered Accountants
FRN: 03173N

S.C. Gupta
(Partner)

Membership No. : **83121**

Place: New Delhi
Date: 04.06.2018

Annexure “B” to the Independent Auditor’s Report of even date on the Financial Statements of Biotech Consortium India Limited**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of Biotech Consortium India Limited (“the Company”) as of March 31, 2018 in conjunction with our audit of the financial statements of the company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and,

both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3)

provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Is over Financial Reporting Inherent Limitations of Internal Financial Controls

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

For Surendra Subhash & Co.
Chartered Accountants
FRN: 03173N

S.C. Gupta
(Partner)

Place: New Delhi
Date: 04.06.2018

Membership No. : **83121**

BALANCE SHEET AS AT 31ST MARCH 2018

(Rs. in lacs)

Particulars		Note No.	As at 31 March, 2018	As at 31 March, 2017
A	EQUITY AND LIABILITIES			
1	Shareholders' Funds			
a	Share Capital	1	537.00	537.00
b	Reserves and Surplus	2	2,091.86	1966.35
			2628.86	2503.35
2	Non Current Liabilities			
a	Long Term Provisions	3	301.66	223.77
			301.66	223.77
3	Current Liabilities			
a	Trade Payables	4	38.88	46.88
b	Other Current Liabilities	5	4542.87	3539.03
			4,581.75	3,585.91
	TOTAL		7512.27	6313.03
B	ASSETS			
1	Non-Current Assets			
a	Fixed Assets			
(i)	Tangible Assets	6	23.87	21.57
b	Non Current Investments	7	6.70	173.57
c	Deferred Tax Assets (net)	20.5	41.56	28.62
d	Long Term Loans and Advances	8	141.66	141.86
e	Other Non Current Assets	9	164.39	150.04
			378.18	515.66
2	Current Assets			
a	Trade Receivables	10	262.49	152.88
b	Cash and Cash Equivalents	11	6865.19	5636.89
c	Short Term Loans and Advances	12	6.41	7.60
			7134.09	5797.37
	TOTAL		7,512.27	6,313.03
	See accompanying notes (1-21) forming part of the financial statements			

In terms of our report attached

For Surendra Subhash & Co.

Chartered Accountants

FRN : 003173N

(S C Gupta)**Partner**

M.N. 83121

(V P Kamboj)**Chairman****For and on behalf of the Board of Directors****(Purnima Sharma)****Managing Director****(Mukesh Gupta)****AGM (Finance) & Company Secretary**

Place : New Delhi

Date : 04.06.2018

**STATEMENT OF PROFIT AND LOSS
FOR THE YEAR ENDED 31ST MARCH, 2018**

(Rs. in lacs)

Particulars		Note No.	For the year ended 31 March, 2018	For the year ended 31 March, 2017
1	Revenue from Operations	13	808.40	734.48
2	Other Income	14	163.78	181.76
3	Total Revenue (1+2)		972.18	916.24
4	Expenses			
a	Employee Benefits Expense	15	507.17	420.26
b	Depreciation and Amortisation Expense	6	12.93	10.98
c	Depreciation on Assets Funded by Grants	6A	-10.20	-7.07
d	Other Expenses	16	325.52	239.05
5	Total Expenses (a to d)		835.42	663.22
6	Profit before exceptional and extraordinary items and tax (3-5)		136.76	253.02
7	Exceptional and Extraordinary items	19.5	33.34	0.00
8	Profit / (Loss) Before Tax (6+7)		170.10	253.02
9	Tax Expense:			
a	Current Tax Expense for Current Year		55.29	85.71
b	Current Tax Expense Relating to Prior Years		1.77	0.02
c	Deferred Tax		-12.94	-1.20
			44.12	84.53
10	Profit / (Loss) for the year (8-9)		125.98	168.49
11	Earnings per share (of Rs. 10/- each):			
	Basic	20.4	2.35	3.14
	Diluted		2.35	3.14
	See accompanying notes (1-21) forming part of the financial statements			

In terms of our report attached.
For Surendra Subhash & Co.
Chartered Accountants
FRN : 003173N

For and on behalf of the Board of Directors

(S C Gupta)
Partner
M.N. 83121

(V P Kamboj)
Chairman

(Purnima Sharma)
Managing Director

(Mukesh Gupta)
AGM (Finance) & Company Secretary

Place : New Delhi
Date : 04.06.2018

CASH FLOW STATEMENT FOR THE YEAR 2017-18

(Rs. in lacs)

Particulars		2017-2018		2016-2017	
A	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit before Tax as per Statement of Profit and Loss		170.10		253.02
	Adjusted for:				
	Depreciation / Amortisation Expenses	2.73		3.91	
	Dividend Income	-2.93		-10.30	
	Interest Income	-159.96		-169.95	
	Other non-operating income	-0.89		-1.51	
	Non Current Liabilities	77.89		25.40	
	Long-Term Loans and Advances	0.20		82.00	
	Other Non-Current Assets	-14.35		-21.74	
			-97.31		-92.19
	Operating Profit/(Loss) before Working Capital Changes		72.79		160.83
	Adjusted for:				
	Trade Receivables	-109.61		-27.82	
	Short-Term Loans and Advances	1.19		8.31	
	Trade Payables	-8.00		-57.03	
	Other Current Liabilities	1,003.84		1,193.08	
			887.42		1,116.54
	Cash generated from Operations		960.21		1,277.37
	Taxes paid (Net)		-57.06		-85.73
	Net cash flow from / (used in) operating activities (A)		903.15		1,191.64
B	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of fixed assets (net)	-5.50		-4.39	
	Dividend Income	166.87		0.00	
	Sale of Investments	2.93		10.30	
	Interest Income	159.96		169.95	
	Other non-operating income	0.89		1.51	
	Net Cash generated from (Used in) Investing Activities (B)		325.15		177.37
C	CASH FLOW FROM FINANCING ACTIVITIES				
	Net Cash generated from / (Used in) Financing Activities (C)		0.00		0.00
	Net (Decrease) in Cash and Cash Equivalents		1,228.30		1,369.01
	Opening Balance of Cash and Cash Equivalents		5,636.89		4267.88
	Closing Balance of Cash and Cash Equivalents		6,865.19		5,636.89

In terms of our report attached.
For Surendra Subhash & Co.
Chartered Accountants
FRN : 003173N

For and on behalf of the Board of Directors

(S C Gupta)
Partner
M.N. 83121

(V P Kamboj)
Chairman

(Purnima Sharma)
Managing Director

(Mukesh Gupta)
AGM (Finance) & Company Secretary

Place : New Delhi
Date : 04.06.2018

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 1 Share Capital

(Rs. in lacs)

Particulars	As at 31 March, 2018		As at 31 March, 2017	
	Number of shares	Rs.	Number of shares	Rs.
(a) Authorised				
Equity shares of Rs. 10 each with voting rights	1,00,00,000	1,000.00	1,00,00,000	1,000.00
(b) Issued				
Equity shares of Rs.10 each with voting rights	53,70,027	537.00	53,70,027	537.00
(c) Subscribed and fully paid up				
Equity shares of Rs.10 each with voting rights	53,70,027	537.00	53,70,027	537.00
Total		537.00		537.00

Particulars								
Notes: (i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:								
Particulars	Opening Balance	Fresh issue	Bonus	ESOP	Conversion	Buy back	Other changes (give details)	Closing Balance
Equity shares with voting rights								
Year ended 31 March, 2018								
- Number of shares	53,70,027	0.00	0.00	0.00	0.00	0.00	0.00	53,70,027
- Amount (Rs. in lacs)	537.00	0.00	0.00	0.00	0.00	0.00	0.00	537.00
Year ended 31 March, 2017								
- Number of shares	53,70,027	0.00	0.00	0.00	0.00	0.00	0.00	53,70,027
- Amount (Rs. in lacs)	537.00	0.00	0.00	0.00	0.00	0.00	0.00	537.00

(ii) The company has only one class of equity shares having a par value of Rs. 10 per share. Each Shareholder is eligible for one vote per share. The dividend proposed by the Board of Directors is subject to the approval of Members except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion of their shareholding.

(iii) Details of shares held by each shareholder holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March, 2018		As at 31 March, 2017	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
Equity shares with voting rights				
IDBI Bank Limited	1,500,004	27.93	1,500,004	27.93
IFCI Limited	1,000,001	18.62	1,000,001	18.62
IDBI Trusteeship Services Ltd. (ICICI Strategic Investments Fund)	10,00,000	18.62	10,00,000	18.62
Administrator of the Specified Undertaking of the Unit Trust of India	300,000	5.59	300,000	5.59

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 2 Reserves and Surplus

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
(a) Deferred Grant Account		
Opening balance	14.34	12.73
Add: Additions during the year (Fixed assets purchased from the grants received during the year)	9.83	9.14
Less: Transferred during the year including Depreciation on assets purchased out of grants	10.30	7.53
Closing balance	13.87	14.34
(b) Surplus / (Deficit) in Statement of Profit and Loss		
Opening balance	1,952.01	1,783.52
Add: Profit / (Loss) for the year	125.98	168.49
Closing balance	2,077.99	1,952.01
Total (a+b)	2,091.86	1,966.35

Note 3 Long-Term Provisions

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
Provision for employee benefits:		
(i) Provision for gratuity (Refer Note 20.2.a)	185.40	123.32
(ii) Provision for leave encashment (Refer Note 20.2.b)	116.26	100.45
Total	301.66	223.77

Note 4 Trade Payables

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
Trade payables (Refer Note 19.2)	38.88	46.88
Total	38.88	46.88

Note 5 Other Current Liabilities

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
Other payables		
(i) Statutory remittances (Contributions to PF, ESIC, GST, TDS etc.)	41.75	29.70
(ii) Project/Customer Advances	4,479.99	3,415.52
(iii) Creditors for Others	8.99	9.18
(iv) Outstanding Expenses	12.14	76.23
(v) Income Tax payable (net of TDS & Advance Tax)	0.00	8.40
Total	4,542.87	3,539.03

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 6 Fixed Assets

(Rs. in lacs)

Tangible Assets-Owned	Gross block				Accumulated depreciation and impairment				Net block	
	Balance as at 1 April, 2017	Additions	Disposals	Balance as at 31 March, 2018	Balance as at 1 April, 2017	Depreciation / amortisation expense for the year	Depreciation / amortisation on assets disposed off	Balance as at 31 March, 2018	Balance as at 31 March, 2018	Balance as at 31 March, 2017
(a) Plant & Machinery-										
Data Centre Equipments*	49.14	0.00	0.10	49.05	46.66	1.02	0.00	47.69	1.36	2.48
(b) Furniture and Fixtures -										
Furniture & Fixtures	36.64	0.00	0.00	36.64	33.25	0.94	0.00	34.19	2.45	3.39
Furniture & Fixtures (NCS-TCP) *	0.11	0.00	0.00	0.11	0.11	0.00	0.00	0.11	0.00	0.01
Furniture & Fixtures (UNEP-GEF) *	0.83	0.00	0.00	0.83	0.01	0.18	0.00	0.19	0.64	0.82
(c) Office Equipments -										
Office Equipments (Others)	24.86	2.31	0.01	27.17	22.39	1.00	0.00	23.39	3.77	2.47
Office Equipments (BITP)*	0.82	0.00	0.00	0.82	0.81	0.00	0.00	0.81	0.01	0.01
Office Equipments (Data Centre)*	13.08	0.00	0.00	13.08	11.64	0.55	0.00	12.19	0.89	1.44
Office Equipments (IPR CELL) *	2.16	0.00	0.00	2.16	2.14	0.00	0.00	2.14	0.01	0.01
Office Equipments (NCS-TCP) *	0.49	0.00	0.00	0.49	0.46	0.00	0.00	0.46	0.02	0.02
Office Equipments (NCS Mgt. Cell) *	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Office Equipments (RCGM) *	2.49	0.00	0.00	2.49	2.32	0.04	0.00	2.36	0.12	0.16
Office Equipments (IGMORIS) *	0.32	0.00	0.00	0.32	0.30	0.00	0.00	0.30	0.02	0.02
Office Equipments (PMU under NCS-TCP) *	0.50	0.00	0.00	0.50	0.48	0.00	0.00	0.48	0.02	0.02
Office Equipments (UNEP GEF) *	1.73	2.34	0.00	4.07	1.21	0.96	0.00	2.17	1.90	0.52
(d) Others -Computers -										
Computer Systems	22.64	3.19	0.00	25.83	21.25	0.78	0.00	22.03	3.80	1.39
Computer Systems-(BITP) *	4.26	0.00	0.00	4.26	4.14	0.00	0.00	4.14	0.12	0.12
Computer Systems-(BIITP) *	0.78	0.00	0.00	0.78	0.74	0.00	0.00	0.74	0.04	0.04
Computer Systems-(BITP_NES) *	0.39	0.00	0.00	0.39	0.37	0.00	0.00	0.37	0.02	0.02
Computer Systems-(IGMORIS) *	8.37	0.00	0.00	8.37	8.15	0.06	0.00	8.21	0.16	0.22
Computer Systems-(IPR Cell) *	3.46	0.00	0.00	3.46	3.32	0.00	0.00	3.32	0.14	0.14
Computer Systems-(NCS-TCP) *	0.72	0.00	0.00	0.72	0.70	0.00	0.00	0.70	0.01	0.01
Computer Systems-(NCS Mgt. Cell) *	10.66	0.00	0.00	10.66	3.45	4.15	0.00	7.60	3.05	7.20
Computer Systems-(Placement Project) *	0.87	0.00	0.00	0.87	0.85	0.00	0.00	0.85	0.02	0.02
Computer Systems-(PMU under NCS-TCP) *	3.28	0.00	0.00	3.28	3.13	0.00	0.00	3.13	0.15	0.15
Computer Systems-(RCGM) *	6.26	0.00	0.00	6.26	6.14	0.00	0.00	6.14	0.11	0.11
Computer Systems-(Award Programme) *	0.35	0.00	0.00	0.35	0.35	0.00	0.00	0.35	0.00	0.00
Computer Systems-(UNEP-GEF) *	7.55	7.49	0.00	15.04	6.79	3.24	0.00	10.03	5.01	0.76
Total	202.75	15.33	0.11	217.97	181.17	12.93	0.00	194.10	23.87	21.57
Previous year	189.69	13.60	0.54	202.75	170.21	10.98	0.00	181.17	21.57	19.48

* Above assets represents assets purchased out of grants.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 6A Fixed Assets (contd.)

(Rs. in lacs)

A.	Depreciation and amortisation relating to continuing operations:		
	Particulars	For the year ended 31 March, 2018	For the year ended 31 March, 2017
	Depreciation and amortisation for the year on tangible assets as per Note 6	12.93	10.98
	Depreciation and amortisation for the year on intangible assets as per Note 6	-10.20	-7.07
	Depreciation and amortisation relating to continuing operations	2.73	3.91

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 7 Non-Current Investments

(Rs. in lacs)

Particulars		As at 31 March, 2018				As at 31 March, 2017			
		No. of Units	Face Value per unit (Rs.)	Cost of Investment	Market Value as on 31.03.18	No. of Units	Face Value per unit (Rs.)	Cost of Investment	Market Value as on 31.03.17
Other investments (At cost) (Long Term)									
(a)	Investment in equity instruments								
1	DLF	20.00	10.00	0.19	0.04	20.00	10.00	0.19	0.02
(b)	Investment in mutual funds								
1	DSP BlackRock TIGER Fund	0.00	0.00	0.00	0.00	145,067.84	10.00	44.54	21.78
2	ICICI Prudential Infra Fund	50,276.52	10.00	9.83	6.66	50,276.52	10.00	9.83	5.98
3	Reliance Div. Power Sec. Fund	0.00	0.00	0.00	0.00	161,683.51	10.00	76.32	41.78
4	Kotak 50 Equity Fund	0.00	0.00	0.00	0.00	29,183.45	10.00	15.00	9.52
5	Sundaram Infrastructure Advantage Fund	0.00	0.00	0.00	0.00	241,816.81	10.00	41.68	53.34
	Total			10.02	6.70			187.56	132.42
	Less: Provision for diminution in value of investments			3.32				13.99	
	Total			6.70				173.57	
	Aggregate amount of quoted investments			10.02				187.56	
	Aggregate market value of listed and quoted investments			6.70				132.42	

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 8 Long-Term Loans and Advances

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
Security Deposits (Unsecured, considered good) including earnest money of Rs. 02.00 lacs (previous year Rs. 02.00 lacs)	74.15	74.15
Loans and advances to staff (Secured, considered good)	48.14	12.76
Income Tax receivable (net of TDS and Advance Tax) for Current Year	16.63	0.00
Income Tax Refund for Previous Years	2.74	54.95
Total	141.66	141.86

Note 9 Other Non-Current Assets

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
Gratuity Fund	84.04	77.41
Leave Encashment Fund	80.35	72.63
Total	164.39	150.04

Note 10 Trade Receivables

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
Trade receivables (outstanding for a period exceeding six months from the date they were due for payment)		
Unsecured, considered good	60.87	56.32
Doubtful	0.00	0.00
	60.87	56.32
Less: Provision for doubtful trade receivables	0.00	0.00
	60.87	56.32
Other Trade receivables		
Unsecured, considered good	201.62	96.56
Less: Provision for doubtful trade receivables	0.00	0.00
	201.62	96.56
Total	262.49	152.88

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 11 Cash and Cash Equivalents

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
(a) Cash in hand	3.40	2.65
(b) Balances with banks		
(i) In current accounts with scheduled banks	311.34	2,623.11
(ii) In Deposit Accounts with scheduled banks (Including Term Deposits of Rs.13.13 lacs (Previous Year - Rs. 20.16 lacs) having lien in favour of HDFC Bank Limited towards bank guarantee provided to DBT for execution of a project)	6,480.14	2,961.53
(iii) Bank deposits with more than twelve months maturity	41.06	38.59
(c) Interest accrued on Fixed Deposit with banks	29.25	11.01
Total	6,865.19	5,636.89

Note 12 Short-Term Loans and Advances

(Rs. in lacs)

Particulars	As at 31 March, 2018	As at 31 March, 2017
(a) Prepaid expenses - Unsecured, considered good	4.99	4.01
(b) Balances with government authorities - Unsecured, considered good		
Service Tax credit receivable/Excess Service Tax Paid	0.00	1.99
(c) Others - Unsecured, considered good		
Advances to staffs	1.40	0.61
Other amount receivable	0.02	0.99
Total	6.41	7.60

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 13 Revenue from Operations

(Rs. in lacs)

Particulars		For the year ended 31 March, 2018	For the year ended 31 March, 2017
(a)	Sale of services including grant in aid received	806.21	732.29
(b)	Other operating revenues	2.19	2.19
Total		808.40	734.48

Note 14 Other Income

(Rs. in lacs)

Particulars		For the year ended 31 March, 2018	For the year ended 31 March, 2017
(a)	Interest Income (Tax deducted at source - Rs. 16.44 lacs (Previous Year -Rs. 16.04 lacs) (Refer note no. (i) below)	159.96	169.95
Interest Income on Project Funds			
	Interest received (Tax deducted at source - Rs. 22.84 lacs (Previous Year -Rs. 11.56 lacs)	229.38	109.47
	Less: Amount credited to Project Funds	-229.38	-109.47
(b)	Dividend income from long-term investments	2.93	10.30
(c)	Other non-operating income (net of expenses directly attributable to such income) (Refer Note (ii) below)	0.89	1.51
Total		163.78	181.76

Particulars		For the year ended 31 March, 2018	For the year ended 31 March, 2017
(i)	Interest income comprises:		
	Interest from banks on deposits	140.14	163.13
	Interest income from long term investments	6.92	6.82
	Interest on income tax refund	12.90	0.00
Total - Interest income		159.96	169.95
(ii)	Other non-operating income comprises:		
	Prior period items (net) (Refer Note (iii) below)	0.00	0.00
	Profit on sale of assets	0.02	0.01
	Miscellaneous income	0.87	1.50
Total - Other non-operating income		0.89	1.51
(iii)	Details of Prior period items (net)		
	Prior period income	0.00	0.00
	Prior period expenses	0.00	0.00
Total		0.00	0.00

NOTES FORMING PART OF THE FINANCIAL STATEMENTS**Note 15 Employee Benefits Expense****(Rs. in lacs)**

Particulars	For the year ended 31 March, 2018	For the year ended 31 March, 2017
Salaries and Wages	345.82	316.68
Managerial Remuneration	35.15	33.94
Lease Rent	2.06	0.87
Contributions to provident and other funds	36.99	34.73
Gratuity and Leave Encashment Expenses incurred	11.67	15.88
Provision made for Gratuity and Leave Encashment Expenses	69.30	12.78
Staff Welfare Expenses	1.41	1.16
Ex Gratia	4.77	4.22
Total	507.17	420.26

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 16 Other Expenses

(Rs. in lacs)

Particulars	For the year ended 31 March, 2018	For the year ended 31 March, 2017
Project Related Expenses	173.99	97.57
Technology Fees	0.44	0.76
Electricity Charges	5.79	6.10
Postage & Telecom Expenses	7.66	6.08
Books & Periodicals Expenses	0.61	0.64
Services Outsourcing Charges	0.00	0.59
Directors' Sitting Fee/Meeting Expenses	1.78	1.94
Bank Charges	0.64	0.68
Filing Fees	0.08	0.10
Interest, Fine & Penalties	0.02	0.20
Service Tax Disallowance A/c	5.22	1.79
Security Transaction Tax	0.00	0.00
Diwali Expenses	0.46	0.33
Rent Including Lease Rentals	94.44	84.54
Repairs & Maintenance - Others	10.92	11.70
Insurance	4.35	3.79
Travelling & Conveyance	12.86	15.07
Printing & Stationery	2.23	0.93
Bad Debts Written Off	0.22	0.20
Legal and Professional Expenses	1.60	2.68
Payments to Auditors (Refer Note (i) below)	1.50	1.51
Loss on foreign currency transactions and translation	0.49	0.35
Miscellaneous Expenses	0.22	1.50
Total	325.52	239.05

(Rs. in lacs)

Notes:	For the year ended 31 March, 2018	For the year ended 31 March, 2017
7Particulars		
(i) Payments to the auditors comprises (net of service tax input credit, where applicable):		
As auditors - statutory audit	1.20	1.21
For tax audit	0.30	0.30
For other services	0.00	0.00
Total	1.50	1.51

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note	Particulars
17	Corporate Information
	Biotech Consortium India Limited (BCIL) is a company promoted by the Department of Biotechnology, Ministry of Science & Technology, Govt. of India (DBT) and financed by all India public financial institutions and corporate(s) with the objective of providing necessary linkages among different stakeholders to facilitate accelerated commercialization of biotechnology. BCIL has been actively involved in technology transfer, project consultancy, project management, biosafety services, IPR related services, information dissemination and manpower training related to biotechnology over the last two and half decade. BCIL is presently managing a number of prestigious projects of national relevance for various government departments including DBT, Ministry of Agriculture (MOA), Ministry of Environment & Forests and Climate Changes (MOEF & CC) and Ministry of External Affairs (MEA). BCIL is closely networking with stakeholders involved in commercialization of biotechnology i.e. Central and State Governments, scientists, research institutions, universities, entrepreneurs, corporate sector and other national and international organizations etc. BCIL has an elite Board of Directors consisting of Heads of various Govt. Departments dealing with research in biotechnology, financial institutions and industry to provide vision and guidance to BCIL in its various activities. Presently, BCIL carries its operations from its corporate and registered office at 5th Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi-110002.
18	Significant Accounting Policies
18.1	Basis of accounting and preparation of Financial Statements
	The Financial Statements of the company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with the Rule 7 of the Companies (Accounts) Rules, 2014. the existing Accounting Standards as notified in the Companies (Accounting Standards) Rules, 2006, as amended from time to time, have been adopted by the Company and disclosures are made in accordance with the requirement of Schedule III of the Companies Act, 2013 as referred under section 129(1) of the Companies Act, 2013. The Financial Statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the Financial Statements are consistent with those followed in the previous year.
18.2	Use of estimates
	The preparation of the Financial Statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believes that the estimates used in preparation of the Financial Statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognised in the periods in which the results are known / materialise.
18.3	Depreciation and amortisation
	<p>i) Depreciation on fixed assets has been provided on pro-rata basis from the date of acquisition of assets on written down value method at the rates arrived at on the basis of remaining useful life of the assets and manner prescribed under Schedule II read with Section 123 of the Companies Act, 2013.</p> <p>ii) On assets sold, discarded etc, during the year, depreciation is provided upto the date of sale /discard. The value of assets whose useful life has been expired, has been adjusted with retained earnings/deferred grants.</p> <p>iii) Depreciation on fixed assets purchased out of capital grants is debited from Capital Reserve Account and credited to Profit and Loss Account, resulting into claiming deprecation only on the assets funded by the company.</p>
18.4	Revenue recognition
	<p>Revenue is recognized on accrual basis to the extent that it is probable that the economic benefits will flow to the Company and can be reliably measured. Accordingly, wherever there are uncertainties in the ascertainment / realization of income, the same is not accounted for.</p> <p>Income from Sale of Publication and Subscription from members is recognised on receipt basis.</p>
18.5	Other income
	The Dividend income from investments made in Companies and Mutual fund units is recognized as and when the Company becomes entitled to it i.e. after the declaration and approval of dividend by the Investee Company / Mutual Fund. Interest income is recognized on accrual basis taking into account, the amount invested and the rate of interest applicable on time proportionate method. Interest on tax refund, if any, is accounted for on receipt basis.
18.6	Tangible fixed assets
	<p>“Fixed assets have been capitalised at cost inclusive of installation expenses and are carried at cost less accumulated depreciation and impairment losses, if any. Subsequent expenditure relating to fixed assets is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.</p> <p>Fixed assets acquired out of grants sanctioned and put to use for project purposes are capitalised and capital reserve in the nature of deferred grant is created for the equivalent amount. Depreciation on such assets is not claimed and amount equivalent to depreciation is reduced from both the fixed assets and deferred grant as well.</p>

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 18 Significant Accounting Policies (contd.)

Note	Particulars
18.7	Intangible assets
	The company do not have any intangible assets for the period under review. However the same are amortised over a period of five years.
18.8	Foreign currency transactions and translations
	<p>Initial recognition</p> <p>Transactions in foreign currencies entered into by the company and its integral foreign operations are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.</p> <p>Measurement of foreign currency monetary items at the Balance Sheet date</p> <p>Year end balances of receivables/ payables are translated at year end rate of exchange and the resultant transaction loss/gain is recognized in the Statement of Profit and Loss.</p>
18.9	Government grants, subsidies and export incentives
	Grants received & utilized from Government agencies against specific fixed assets are shown under the head “Capital Reserve”- Sub head “Deferred Grant” and depreciation on the fixed assets purchased out of grants are debited to Deferred Grant Account and credited to the Depreciation Account and depreciation in Profit and Loss Account is shown seperately. Revenue grants are shown in the profit and loss account to match the same with the related costs as per the terms of grants and unutilized grants are shown under the head “Advances Received”.
18.10	Investments
	Investments being long term in nature are stated at cost and provision for diminution in their value other than temporary is made in the financial statements. Gains/ losses on disposal/redemption of investments are recognized as income/ expenditure, as and when realized and temporary decline in the value of investments are not recognized as loss in accordance with the Accounting Standard -13 (AS-13) issued by ICAI.
18.11	Employee benefits
	<p>Employee benefits include provident fund, gratuity and leave encashment.</p> <p>Defined contribution plans</p> <p>The company’s contribution to provident fund are considered as defined contribution plans and are charged as an expense as they fall due based on the amount of contribution required to be made.</p> <p>Defined benefit plans</p> <p>For defined benefit plans in the form of gratuity fund and leave encashment fund, the cost of providing benefits is determined using the Projected Unit Credit method, with actuarial valuations being carried out at each Balance Sheet date. Actuarial gains and losses are recognised in the Statement of Profit and Loss in the period in which they occur. Past service cost is recognised immediately to the extent that the benefits are already vested and otherwise is amortised on a straight-line basis over the average period until the benefits become vested. The retirement benefit obligation recognised in the Balance Sheet represents the present value of the defined benefit obligation as adjusted for unrecognised past service cost, as reduced by the fair value of scheme assets. Any asset resulting from this calculation is limited to past service cost, plus the present value of available refunds and reductions in future contributions to the schemes.</p>
18.12	Earnings per share
	Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share from continuing ordinary operations. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits / reverse share splits and bonus shares, as appropriate.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 18 Significant Accounting Policies (contd.)

Note	Particulars
18.13	Taxes on income
	<p>“Current tax is the amount of tax payable on the taxable income for the year as determined in accordance with the provisions of the Income Tax Act, 1961.</p> <p>Minimum Alternate Tax (MAT) paid in accordance with the tax laws, which gives future economic benefits in the form of adjustment to future income tax liability, is considered as an asset if there is convincing evidence that the company will pay normal income tax. Accordingly, MAT is recognised as an asset in the Balance Sheet when it is probable that future economic benefit associated with it will flow to the company.</p> <p>Deferred tax is recognised on timing differences, being the differences between the taxable income and the accounting income that originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or substantially enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences. Deferred tax assets in respect of unabsorbed depreciation and carry forward of losses are recognised only if there is virtual certainty that there will be sufficient future taxable income available to realise such assets. Deferred tax assets are recognised for timing differences of other items only to the extent that reasonable certainty exists that sufficient future taxable income will be available against which these can be realised. Deferred tax assets and liabilities are offset if such items relate to taxes on income levied by the same governing tax laws and the Company has a legally enforceable right for such set off. Deferred tax assets are reviewed at each Balance Sheet date for their realisability. “</p> <p>Current and deferred tax relating to items directly recognised in equity are recognised in equity and not in the Statement of Profit and Loss.</p>
18.14	Provisions and contingencies
	<p>A provision is recognised when the company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions (excluding retirement benefits) are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the Balance Sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. Contingent liabilities are disclosed in the Notes.</p>
18.15	Service tax/GST input tax credit
	<p>Service tax/GST input tax credit is accounted for in the books in the period in which the Invoice of GST received is accounted and when there is no uncertainty in availing / utilising the credits and no Input tax credit is taken on provisional Basis.</p>
18.16	Impairment of Assets
	<p>The management periodically assesses, whether there is an indication that an asset may be impaired. An impairment loss is recognized wherever the carrying value of an asset exceeds its recoverable amount. The recoverable amount is higher of the assets net selling price and value in use, which means the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. An impairment loss, if any, is charged to the Statement of Profit and Loss in the year in which the asset is identified as impaired. The impaired loss recognized in prior accounting periods is reversed/adjusted, if there has been a change in the estimate of the recoverable amount.</p>
18.17	Cash Flow Statement
	<p>Cash flows are reported using the indirect method, whereby profit before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated based on the available information.</p>

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 19 Additional information to the financial statements

(Rs. in lacs)

Note	Particulars	As at 31 March, 2018	As at 31 March, 2017
19.1	Contingent liabilities and commitments (to the extent not provided for)		
(i)	Contingent liabilities		
	(a) Claims against the company not acknowledged as debt	0.00	0.00
	(b) Performance Bank Guarantees	13.13	20.16
	(c) Other money for which the Company is contingently liable	0.00	0.00
(ii)	Commitments		
	(a) Estimated amount of contracts remaining to be executed on capital account and not provided for		
	Tangible assets	0.00	0.00
	Intangible assets	0.00	0.00
	(b) Uncalled liability on shares and other investments partly paid	0.00	0.00
	(c) Other commitments	0.00	0.00
19.2	Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006		
	Particulars	As at 31 March, 2018	As at 31 March, 2017
	(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year	38.88	46.88
	(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year	0.00	0.00
	(iii) The amount of interest paid along with the amounts of the payment made to the supplier beyond the appointed day	0.00	0.00
	(iv) The amount of interest due and payable for the year	0.00	0.00
	(v) The amount of interest accrued and remaining unpaid at the end of the accounting year	0.00	0.00
	(vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above are actually paid	0.00	0.00
	Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified by the Management and relied upon by the Auditors.		
19.3	Earnings in foreign currency:	As at 31 March, 2018	As at 31 March, 2016
	Export of goods calculated on FOB basis	0.00	0.00
	Royalty, know-how, professional and consultation fees	75.37	88.18
	Interest and dividend	0.00	0.00
	Other income, indicating the nature thereof.	0.00	0.00
19.4	Expenditure in foreign exchange:	As at 31 March, 2018	As at 31 March, 2017
	Royalty	0.00	0.00
	Know-how	0.00	0.00
	Project related expenses	1.70	2.58
	Interest	0.00	0.00
	Other matters	0.00	0.00
19.5	Exceptional, Extraordinary and Prior Period Items	As at 31 March, 2018	As at 31 March, 2017
	Profit on sale of Long Term Investments	46.01	0.00
	Loss on sale of Long Term Investments	-24.17	0.00
	Provision for decline in value of investments written back	10.67	0.00
	Prior Period Income	0.83	0.00
	Total	33.34	0.00

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 20 Disclosures under Accounting Standards

(Rs. in lacs)

Note	Particulars	For the year ended 31 March, 2018	For the year ended 31 March, 2017
20.1	Details of government grants		
20.1.a	Government grants received by the company during the year towards Subsidies, Duty drawback and other incentives	NIL	NIL
20.1.b	The company has received certain equipments and facilities free of cost/Purchase out of grant during the year from the Department of Biotechnology, Govt. of India (DBT) and Ministry of Environment & Forests and Climate Changes, Govt. of India (MOEF & CC) towards implementing various projects on behalf of the DBT & MOEF.	9.83	9.14
Note	Particulars		
20.2	Retirement benefits		
20.2.a	A total provision for gratuity of Rs. 185.40 lacs has been made by the company as per the valuation certificate provided by the Life Insurance Corporation of India. To meet the liability towards gratuity, the company has taken coverage from the Life Insurance Corporation of India under its Group Gratuity Cash Accumulation Scheme to the extent of Rs. 84.04 lacs.		
20.2.b	A total provision for leave encashment of Rs. 116.26 lacs has been made by the company as per the valuation certificate provided by the Life Insurance Corporation of India. To meet the liability towards leave encashment, the Company has taken coverage from the Life Insurance Corporation of India under its Group Leave Encashment Scheme to the extent of Rs. 80.35 lacs.		

Note	Particulars	
20.3	Related party transactions	
20.3.a	Details of related parties:	
	Description of relationship	Names of related parties
	Associates	IDBI Bank Limited
	Key Management Personnel (KMP)	Dr. Purnima Sharma Mr. Mukesh Gupta
	Note: Related parties have been identified by the Management.	

20.3.b	Particulars	Associates	KMP	Beneficiary companies	Total
		Rs.	Rs.	Rs.	Rs.
	Payment for services (Salaries & perquisites)	0.00	56.40	0.00	56.40
		(0.00)	(53.16)	(0.00)	(53.16)
	Bank Deposits	3388.35	0.00	0.00	3388.35
		(974.37)	(0.00)	(0.00)	(974.37)
	Receipt of Interest	214.82	0.00	0.00	214.82
		(54.06)	(0.00)	(0.00)	(54.06)
	Note: Figures in bracket relates to the previous year				

NOTES FORMING PART OF THE FINANCIAL STATEMENTS**Note 20 Disclosures under Accounting Standards (contd.)****(Rs. in lacs)**

Note	Particulars	For the year ended 31 March, 2018	For the year ended 31 March, 2017
20.4	Earnings per share		
	Basic & Diluted		
20.4.a	Continuing operations		
	Net profit / (loss) for the year from continuing operations	125.98	168.49
	Less: Preference dividend and tax thereon	0.00	0.00
	Net profit / (loss) for the year from continuing operations attributable to the equity shareholders	125.98	168.49
	Weighted average number of equity shares	53,70,027.00	53,70,027.00
	Par value per share	10.00	10.00
	Earnings per share from continuing operations - Basic	2.35	3.14
20.4.b	Total operations		
	Net profit / (loss) for the year	125.98	168.49
	Less: Preference dividend and tax thereon	0.00	0.00
	Net profit / (loss) for the year attributable to the equity shareholders	125.98	168.49
	Weighted average number of equity shares	5,370,027.00	5,370,027.00
	Par value per share	10.00	10.00
	Earnings per share - Basic	2.35	3.14

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 20 Disclosures under Accounting Standards (contd.)

(Rs. in lacs)

Note	Particulars	As at 31 March, 2018	As at 31 March, 2017
20.5	Deferred tax (liability) / asset		
	Tax effect of items constituting deferred tax liability		
	On difference between book balance and tax balance of fixed assets	0.00	0.00
	On expenditure deferred in the books but allowable for tax purposes	0.00	0.00
	On items included in reserves and surplus pending amortisation into the Statement of Profit and Loss	0.00	0.00
	Others	0.00	0.00
	Tax effect of items constituting deferred tax liability	0.00	0.00
	Tax effect of items constituting deferred tax assets		
	Provision for compensated absences, gratuity and other employee benefits	38.52	24.38
	Provision for doubtful debts / advances	0.00	0.00
	Disallowances under Section 40(a)(i), 43B of the Income Tax Act, 1961	0.00	0.37
	On difference between book balance and tax balance of fixed assets	3.04	3.87
	Unabsorbed depreciation carried forward	0.00	0.00
	Brought forward business losses	0.00	0.00
	On items included in reserves and surplus pending amortisation into the Statement of Profit and Loss	0.00	0.00
	Others	0.00	0.00
	Tax effect of items constituting deferred tax assets	41.56	28.62
	Net deferred tax (liability) / asset	41.56	28.62
	The company has recognised deferred tax asset on unabsorbed depreciation and brought forward business losses based on the Management's estimates of future profits considering the non-cancellable customer orders received by the company. Provision for Gratuity, Provision for Leave Encashment and Provision for doubtful debts are considered based on Management's estimates.		

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

Note 20 Disclosures under Accounting Standards (contd.)

Note	Particulars
20.6	In the opinion of the Board, the value of current assets, loans and advances have a realizable value in the ordinary course of business at least equal to that stated in the Balance Sheet.
20.7	Balances in respect of receivables, sundry debtors, project advances and creditors are subject to their confirmations. Amount receivable from Government agencies including DBT, MOEF & CC etc. and project advances in various projects amounting to Rs. 4480.00 lacs can not be confirmed due to the difference in the method of accounting deployed in these agencies and the company 's method of accounting. The balances in project advances represent unspent balance from the projects funds granted by these agencies and the same are utilized for the projects as per sanction order received from these agencies from time to time.
20.8	The company had entered into agreements with DBT & MOEF & CC under the various schemes of DBT where by it is acting as a coordinating /managing agency. The funds received from DBT under various schemes have been kept separately in bank accounts and interest earned on these deposits is credited to the respective DBT project accounts. The interest earned is utilized only for activities to be carried on under the various schemes. However the interest earned on these funds and liability to pay such interest to the DBT has been shown net of Income & Expenditure while preparing Statement of Profit & Loss Account. These funds are specifically utilized for the schemes of DBT and only the fees received for rendering services as coordinating/managing agency has been accounted for as income from operation in the Statement of Profit and Loss. The company is maintaining details of head wise expenditure incurred in projects coordinated by it through cost categories and cost centers.

Note 21 Previous year's figures	
Note	Particulars
21	Previous year's figures have been regrouped / reclassified wherever necessary to correspond with the current year's classification / disclosure.

In terms of our report attached.
For Surendra Subhash & Co.
 Chartered Accountants
 FRN : 003173N

For and on behalf of the Board of Directors

(S C Gupta)
 Partner
 M.N. 83121


(V P Kamboj)
 Chairman

(Purnima Sharma)
 Managing Director

(Mukesh Gupta)
 AGM (Finance) & Company Secretary

Place : New Delhi
 Date : 04.06.2018

Route Map of AGM Venue



BIOTECH CONSORTIUM INDIA LIMITED

**Regd. Office: 5th Floor, Anuvrat Bhawan,
210, Deen Dayal Upadhyaya Marg,
New Delhi - 110002**

ATTENDANCE SLIP*

I hereby record my presence at the 28th Annual General Meeting of the company at the registered office of the company at 5th Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi-110 002 at 10:30 a.m. on Tuesday, the 14th day of August 2018.

Full Name of the Shareholder
(in Capitals)

Signature

Folio No.:

*Shareholders attending the meeting in person or by proxy are requested to complete the attendance slip and hand it over at the entrance of the meeting hall.

BIOTECH CONSORTIUM INDIA LIMITED

**Regd. Office: 5th Floor, Anuvrat Bhawan,
210, Deen Dayal Upadhyaya Marg,
New Delhi - 110002**

PROXY FORM

I/we _____
_____ of _____ in the district of _____
_____ being a member/members of the above-named company, hereby appoint _____
of _____, or failing him/her _____ of _____ as my/
our proxy to vote for me/us on my/our behalf at the 28th Annual General Meeting of the company to be held on 14th
day of August 2018 and at any adjournment thereof.

Signed this _____ day of _____ 2018.

Signature

